Evaluation of predictive biomarkers for nivolumab in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) from the CheckMate-025 (CM-025) trial.

Abstract

5023

Document Details

Document Type
Pub Defense Publication
Publication Date
May 20, 2020
Source ID
10.1200/jco.2020.38.15_suppl.5023

Entities

People

  • Arlene Sharpe
  • Catherine J Wu
  • David A Braun
  • David F McDermott
  • Eliezer Mendel Van Allen
  • F Stephen Hodi
  • Gordon J. Freeman
  • Jean-christophe Pignon
  • Maxine Sun
  • Megan Wind-Rotolo
  • Michael B Atkins
  • Miriam Ficial
  • Miriam Sant’angelo
  • Opeyemi Jegede
  • Paul J. Catalano
  • Robert J. Motzer
  • Sabina Signoretti
  • Sachet A Shukla
  • Sonia Moreno
  • Toni K Choueiri

Organizations

  • Beth Israel Deaconess Medical Center
  • Brigham and Women's Hospital
  • Bristol-Myers Squibb
  • Dana–Farber Cancer Institute
  • Georgetown Lombardi Comprehensive Cancer Center
  • Harvard Medical School
  • Memorial Sloan Kettering Cancer Center
  • National Institutes of Health
  • United States Department of Defense

Tags

Fields of Study

  • Medicine